Sildenafil drug interactions | Litt's Drug Eruption and Reaction Database

Sildenafil

TRADE NAMES: Revatio (Pfizer); Viagra (Pfizer)
INDICATIONS: Erectile dysfunction, hypertension
CLASS: COVID-19 putative drug, Phosphodiesterase type 5 (PDE5) inhibitor
HALF-LIFE: 4 hours

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfuzosin, Alpha blockers, Amlodipine, Amprenavir, Amyl Nitrite, Antifungals, Antihypertensives, Atazanavir, Boceprevir, Bosentan, Cimetidine, Clarithromycin, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Conivaptan, CYP3A4 inhibitors and inducers, Darunavir, Dasatinib, Deferasirox, Delavirdine, Disopyramide, Erythromycin, Etravirine, Fosamprenavir, Grapefruit Juice, High-fat foods, HMG-CoA reductase inhibitors, Indinavir, Isosorbide, Isosorbide Dinitrate, Isosorbide Mononitrate, Itraconazole, Ketoconazole, Lopinavir, Macrolide antibiotics, Nelfinavir, Nicorandil, Nitrates, Nitroglycerin, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Other phosphodiesterase 5 inhibitors, Paclitaxel, PEG-Interferon, Riociguat, Ritonavir, Sapropterin, Saquinavir, St John's Wort, Telaprevir, Telithromycin, Tipranavir

PREGNANCY CATEGORY: B

Under investigation for treating COVID-19

See adverse reactions attributed to class:

COVID-19 putative drug

Phosphodiesterase type 5 (PDE5) inhibitor

Dermatitis <2%

(package insert)

Diaphoresis <2%

(2004): Deveci S+, Int J Urol 11(11), 989

DRESS syndrome

(2020): Gupta SK+, Dermatol Ther Jun, Online ahead of print (1 case / male)

Edema <2%

(package insert)

Erythema 6%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]6%

Exfoliative dermatitis <2%

(package insert)

Facial edema <2%

(package insert)

Facial flushing

(2011): Jin Z+, Asian J Androl 13(4), 6305%

Flushing 10–25%

(2017): Gong B+, Int Urol Nephrol 49(10), 1731 [REVIEW]

(2017): Graziano S+, Eur Rev Med Pharmacol Sci 21(1 Suppl), 17 [REVIEW] (passim)

(2017): Tu JH+, Pediatr Dermatol 34(5), 559 (mild)

(2016): Ventimiglia E+, Expert Opin Drug Saf 15(2), 141 [REVIEW]

(2015): Bai WJ+, Asian J Androl 17(1), 612%

(2015): Balhara YP+, Indian J Endocrinol Metab 19(4), 451 [REVIEW]

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]10%

(2014): Murdaca G+, Expert Opin Drug Saf 13(3), 295

(2013): Seferian A+, Eur Respir Rev 22(129), 217

(2013): Wijitsettakul U+, J Med Assoc Thai 96(6), 68313%

(2012): Lederer DJ+, COPD 9(3), 268

(2012): Xiao Y+, Cochrane Database Syst Rev 4, CD009427 [REVIEW]

(2011): Cvelich RG+, Ann Pharmacother 45(12), 1551

(2011): Lee M, Clin Ther 33(11), 1590 [REVIEW]

(2010): Benard F+, J Sex Med 7(11), 3725

(2010): Harrington C+, J Med Imaging Radiat Oncol 54(3), 2248–10%

(2008): Afif-Abdo J+, BJU Int 102(7), 829

(2006): Blonde L, Curr Med Res Opin 22(11), 21117%

(2005): Sunwoo S+, Int J Impot Res 17(1), 716%

(2004): DeBusk RF+, Am J Cardiol 93(2), 147

(2004): Deveci S+, Int J Urol 11(11), 989

(2003): Berman JR+, J Urol 170(6 Pt 1), 2333

(2003): Carson CC, Expert Opin Pharmacother 4(3), 397

(2003): Govier F+, Clin Ther 25(11), 27095%

(2003): Stroberg P+, Clin Ther 25(11), 27247%

(2002): Becher E+, Int J Impot Res 14, S33-41

(2002): Coelho OR, Int J Impot Res 14, S54

(2002): Fink HA+, Arch Intern Med 162(12), 1349 [REVIEW]12%

(2002): Glina S+, Int J Impot Res 14, S27-32

(2002): Lim PH+, Ann N Y Acad Sci 962, 378 [REVIEW]

(2002): Salonia A+, J Urol 168(6), 2486 (with paroxetine)

(2001): Chen KK+, Int J Impot Res 13(4), 22125%

(2001): Rosenkranz S+, Dtsch Med Wochenschr 126(41), 1144 [REVIEW]

(2001): Steers W+, Int J Impot Res 13(5), 261

Genital edema <2%

(package insert)

Herpes simplex <2%

(package insert)

Hypersensitivity

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW] (2 cases)

Lichenoid eruption

(2005): Antiga E+, J Dermatol 32(12), 972

(2000): Goldman BD, Cutis 65 (5), 282

Melanoma

(2014): Li WQ+, JAMA Intern Med 174(6), 964

Peripheral edema <2%

(2013): Morris CR+, Haematologica 98(9), 1359

Photosensitivity <2%

(package insert)

Pigmented purpuric eruption

(2013): Kocak AY+, Cutan Ocul Toxicol 32(1), 91

Pruritus (itching) <2%

(package insert)

Rash 2%

(package insert)

Ulcerations <2%

(package insert)

Urticaria <2%

(package insert)

Epistaxis (nosebleed) 9–13%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]9%

(2012): Lederer DJ+, COPD 9(3), 268

Gingivitis <2%

(package insert)

Glossitis <2%

(package insert)

Nasal congestion

(2016): Ventimiglia E+, Expert Opin Drug Saf 15(2), 141 [REVIEW]

(2015): Bai WJ+, Asian J Androl 17(1), 611%

(2013): Wijitsettakul U+, J Med Assoc Thai 96(6), 68310%

(2012): Lederer DJ+, COPD 9(3), 268

(2010): Benard F+, J Sex Med 7(11), 3725

(2010): Harrington C+, J Med Imaging Radiat Oncol 54(3), 2248–10%

(2008): Afif-Abdo J+, BJU Int 102(7), 829

Rectal hemorrhage <2%

(package insert)

Rhinorrhea

(2016): Ventimiglia E+, Expert Opin Drug Saf 15(2), 141 [REVIEW]

Stomatitis (oral mucositis) <2%

(package insert)

Xerostomia (dry mouth) <2%

(package insert)

Angina <2%

(2013): Alekperov RT+, Ter Arkh (Russian) 85(5), 60 (exacerbation)

Aortic dissection

(2006): Nachtnebel A+, South Med J 99(10), 1151

Atrial fibrillation

(2013): Alekperov RT+, Ter Arkh (Russian) 85(5), 60

(2004): Kingma JH+, J Am Coll Cardiol 44(11), 2117 [REVIEW]

Atrioventricular block <2%

(package insert)

Cardiac arrest <2%

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

(2011): Huber BC+, BMC Cardiovasc Disord 11, 49

Cardiac disorder

(2019): Olcina Rodriguez J+, Rev Int Androl (Spanish) May, Epub ahead of print [REVIEW] (with cannabis)

Cardiac failure <2%

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

Cardiomyopathy <2%

(package insert)

Cardiotoxicity

(2015): Balhara YP+, Indian J Endocrinol Metab 19(4), 451 [REVIEW]

Chest pain <2%

(2013): Ekinozu I+, Am J Emerg Med 31(9), 1424.e1

(2012): Lederer DJ+, COPD 9(3), 268

Congestive heart failure

(2013): Alekperov RT+, Ter Arkh 85(5), 60

(2010): Zisman DA+, N Engl J Med 363(7), 6201%

Hypotension <2%

(2016): Fender RA+, J Pediatr Pharmacol Ther 21(5), 419

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

(2012): Lombardi G+, J Sex Med 9(4), 970 [REVIEW]

(2010): Blaise S+, Br J Pharmacol 160(5), 1128 (1 case)

(2006): Nieminen T+, Clin Drug Investig 26(11), 667 (with tamsulosin)

Myocardial infarction

(2013): Alekperov RT+, Ter Arkh (Russian) 85(5), 60 (fatal) Fatal

(2012): Cakmak HA+, BMJ Case Rep Oct, Epub

(2007): Velasquez Lopez JG+, Actas Urol Esp 31(1), 52

(2006): Saha SA+, Am J Ther 13(4), 378

Myocardial ischemia <2%

(package insert)

Palpitation <2%

(2011): Jin Z+, Asian J Androl 13(4), 6302%

Phlebitis

(2013): Morris CR+, Haematologica 98(9), 1359

Postural hypotension <2%

(package insert)

Tachycardia <2%

(package insert)

Torsades de pointes

(2007): Falcon-Chevere JL+, Bol Asoc Med P R 99(4), 325 (1 case)

Vasodilation

(2011): Alexander MS+, Spinal Cord 49(2), 273

(2011): Kennedy SH+, Int Clin Psychopharmacol 26(3), 151

(2008): Afif-Abdo J+, BJU Int 102(7), 829

Ventricular arrhythmia

(2016): Heranval A+, Rev Neurol (Paris) 172(4-5), 318 (in Parkinson's disease)

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW] (2 cases)

Central Nervous System

Abnormal dreams <2%

(package insert)

Amnesia

(2006): Shihman B+, Harefuah 145(9), 656

(2003): Gandolfo C+, Neurol Sci 24(3), 145

(2002): Savitz SA+, Neurology 59(5), 778

Anorgasmia <2%

(package insert)

Anxiety

(2010): Perkovic O+, Int J Clin Pharmacol Ther 48 (1), 76

Chills <2%

(package insert)

Choreoathetosis

(2010): Perkovic O+, Int J Clin Pharmacol Ther 48 (1), 76

Depression <2%

(package insert)

Fever (pyrexia) 6%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]6%

Headache 16–46%

(2020): Hao Y+, Life Sci Jul, Online ahead of print [REVIEW] (mild)

(2017): Dunn L+, Fetal Diagn Ther 41(2), 81 [REVIEW]46%

(2017): Graziano S+, Eur Rev Med Pharmacol Sci 21(1 Suppl), 17 [REVIEW] (passim)

(2017): Ohl DA+, Sex Med Rev 5(4), 52116%

(2016): Ventimiglia E+, Expert Opin Drug Saf 15(2), 141 [REVIEW]

(2015): Bai WJ+, Asian J Androl 17(1), 611%

(2015): Balhara YP+, Indian J Endocrinol Metab 19(4), 451 [REVIEW]

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]46%

(2013): Alekperov RT+, Ter Arkh (Russian) 85(5), 60

(2013): Buvat J+, J Sex Med 10(6), 1592>4%

(2013): Lasaponara F+, J Sex Med 10(11), 2798

(2013): Morris CR+, Haematologica 98(9), 1359 (transient)

(2013): Seferian A+, Eur Respir Rev 22(129), 217

(2013): Wijitsettakul U+, J Med Assoc Thai 96(6), 6834%

(2012): Lederer DJ+, COPD 9(3), 268

(2012): Xiao Y+, Cochrane Database Syst Rev 4, CD009427 [REVIEW]

(2011): Alexander MS+, Spinal Cord 49(2), 273

(2011): Cvelich RG+, Ann Pharmacother 45(12), 1551

(2011): Herrick AL+, Arthritis Rheum 63(3), 775

(2011): Jin Z+, Asian J Androl 13(4), 6306%

(2011): Kennedy SH+, Int Clin Psychopharmacol 26(3), 151

(2011): Lee M, Clin Ther 33(11), 1590 [REVIEW]

(2010): Benard F+, J Sex Med 7(11), 3725

(2008): Afif-Abdo J+, BJU Int 102(7), 829

(2008): Ergin S+, J Spinal Cord Med 31(5), 522

(2008): Simonneau G+, Ann Intern Med 149(8), 52157% (with epoprostenol)

(2006): Blonde L, Curr Med Res Opin 22(11), 21115%

(2006): de L Figuerola M+, Cephalalgia 26(5), 617

(2006): Heymann WR, J Am Acad Dermatol 55(3), 501

(2006): Oliver JJ+, Hypertension 48(4), 622

(2005): Sunwoo S+, Int J Impot Res 17(1), 713%

(2004): DeBusk RF+, Am J Cardiol 93(2), 147

(2004): Deveci S+, Int J Urol 11(11), 989

(2003): Berman JR+, J Urol 170(6 Pt 1), 2333

(2003): Carson CC, Expert Opin Pharmacother 4(3), 397

(2003): Govier F+, Clin Ther 25(11), 27099%

(2003): Raina R+, Urology 62(6), 1103

(2003): Stroberg P+, Clin Ther 25(11), 27244%

(2002): Becher E+, Int J Impot Res 14, S33

(2002): Coelho OR, Int J Impot Res 14, S5419%

(2002): Glina S+, Int J Impot Res 14, S27

Hyperesthesia <2%

(package insert)

Insomnia 7%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]7%

Ischemic stroke

(2012): Stefanovic-Budimkic M+, Clin Neurol Neurosurg 114(4), 405

Migraine <2%

(package insert)

Neurotoxicity <2%

(package insert)

Pain <2%

(package insert)

Paresthesias 3%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]3%

Seizures

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW] (1 case)

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

(2002): Gilad R+, BMJ 325(7369), 869

Somnolence (drowsiness) <2%

(package insert)

Spinal cord infarction

(2012): Walden JE+, AJNR Am J Neuroradiol 33(3), e32

Stroke

(2012): Stefanovic-Budimkic M+, Clin Neurol Neurosurg 114(4), 405

(2006): Habek M+, Clin Neuropharmacol 29(3), 165

Subarachnoid hemorrhage

(2011): De-Giorgio F+, Am J Forensic Med Pathol 32(4), 310 (fatal) Fatal

(2008): Kaneria MV+, J Assoc Physicians India 56, 809

Syncope <2%

(2014): Liss MA+, J Endourol 28(10), 1241 (1 case) (with solifenacin)

Tremor <2%

(package insert)

Vertigo / dizziness 2%

(2017): Tu JH+, Pediatr Dermatol 34(5), 559

(2015): Bai WJ+, Asian J Androl 17(1), 611%

(2013): Alekperov RT+, Ter Arkh (Russian) 85(5), 60

(2013): Morris CR+, Haematologica 98(9), 1359

(2013): Wijitsettakul U+, J Med Assoc Thai 96(6), 6833%

(2012): Lederer DJ+, COPD 9(3), 268

(2011): Jin Z+, Asian J Androl 13(4), 6305%

Endocrine/Metabolic

Gynecomastia <2%

(package insert)

Hyperglycemia <2%

(package insert)

Hypernatremia <2%

(package insert)

Hyperuricemia <2%

(package insert)

Gastrointestinal/Hepatic

Abdominal pain <2%

(2012): Lederer DJ+, COPD 9(3), 268

(2011): Jin Z+, Asian J Androl 13(4), 6301% (with doxazosin)

(2008): Afif-Abdo J+, BJU Int 102(7), 829

Colitis <2%

(package insert)

Diarrhea 3–9%

(2017): Wang S+, Acta Otolaryngol 137(6), 674 (mild) (transient)

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]9%

(2014): Murdaca G+, Expert Opin Drug Saf 13(3), 295

(2011): Jin Z+, Asian J Androl 13(4), 6301%

Dyspepsia 7–17%

(2017): Dunn L+, Fetal Diagn Ther 41(2), 81 [REVIEW]16%

(2017): Graziano S+, Eur Rev Med Pharmacol Sci 21(1 Suppl), 17 [REVIEW] (passim)

(2016): Ventimiglia E+, Expert Opin Drug Saf 15(2), 141 [REVIEW]

(2015): Balhara YP+, Indian J Endocrinol Metab 19(4), 451 [REVIEW]

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]13%

(2014): Murdaca G+, Expert Opin Drug Saf 13(3), 295

(2013): Seferian A+, Eur Respir Rev 22 (129), 217

(2013): Wijitsettakul U+, J Med Assoc Thai 96(6), 6831%

(2012): Xiao Y+, Cochrane Database Syst Rev 4, CD009427 [REVIEW]

(2011): Herrick AL+, Arthritis Rheum 63(3), 775

(2011): Jin Z+, Asian J Androl 13(4), 6302%

(2011): Kennedy SH+, Int Clin Psychopharmacol 26(3), 151

(2010): Harrington C+, J Med Imaging Radiat Oncol 54(3), 2248–10%

(2008): Afif-Abdo J+, BJU Int 102(7), 829

(2008): Simonneau G+, Ann Intern Med 149(8), 52116% (with epoprostenol)

Dysphagia <2%

(package insert)

Enterocolitis

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW] (1 case)

Esophagitis <2%

(package insert)

Gastritis <2%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]3%

Gastroenteritis <2%

(package insert)

Gastrointestinal disorder

(2020): Hao Y+, Life Sci Jul, Online ahead of print [REVIEW] (mild)

(2010): Zisman DA+, N Engl J Med 363(7), 6202%

Hepatotoxicity

(2017): Graziano S+, Eur Rev Med Pharmacol Sci 21(1 Suppl), 17 [REVIEW]

(2016): Nissan R+, Curr Drug Saf 11(2), 184 (in a herbal preparation)

Nausea

(2017): Tu JH+, Pediatr Dermatol 34(5), 559 (transient)

(2015): Balhara YP+, Indian J Endocrinol Metab 19(4), 451 [REVIEW]

(2013): Lasaponara F+, J Sex Med 10(11), 2798

(2008): Simonneau G+, Ann Intern Med 149(8), 52125% (with epoprostenol)

Vomiting <2%

(package insert)

Cystitis <2%

(package insert)

Ejaculatory dysfunction <2%

(package insert)

Erection

(2006): Nachtnebel A+, South Med J 99(10), 1151

Nocturia <2%

(package insert)

Priapism

(2005): Kumar R+, Natl Med J India 18(1), 49

(2004): Cantrell FL, Pediatr Emerg Care 20(5), 314

(2002): Goldmeier D+, BMJ 324(7353), 1555 (with Dihydrocodeine)

(2000): Kassim AA+, Blood 95(5), 1878

(2000): Sur RL+, Urology 55, 950

(1999): Aoyagi T+, Bull Tokyo Dent Coll 40(4), 215

Urinary frequency <2%

(package insert)

Urinary incontinence <2%

(package insert)

Urinary tract infection 3%

(2017): Ohl DA+, Sex Med Rev 5(4), 52112%

Anemia <2%

(package insert)

Hemoglobin decreased

(2013): Morris CR+, Haematologica 98(9), 1359

Leukocytopenia (leukopenia) <2%

(package insert)

Prothrombin time increased

(2013): Morris CR+, Haematologica 98(9), 1359

Neuromuscular/Skeletal

Arthralgia <2%

(package insert)

Asthenia / fatigue <2%

(2013): Morris CR+, Haematologica 98(9), 1359

(2011): Jin Z+, Asian J Androl 13(4), 6301%

Ataxia <2%

(package insert)

Back pain

(2015): Bai WJ+, Asian J Androl 17(1), 611%

(2013): Morris CR+, Haematologica 98(9), 1359

(2012): Lederer DJ+, COPD 9(3), 268

Bone or joint pain <2%

(package insert)

Gouty tophi <2%

(package insert)

Hypertonia <2%

(package insert)

Myalgia/Myositis/Myopathy/Myotoxicity 7%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]7%

(2014): Frantz RP+, J Cardiovasc Pharmacol Ther 19(6), 550

(2006): Heymann WR, J Am Acad Dermatol 55(3), 501

(2006): Oliver JJ+, Hypertension 48(4), 622

Pain in extremities

(2008): Simonneau G+, Ann Intern Med 149(8), 52118% (with epoprostenol)

Rhabdomyolysis

(2010): Pennisi G+, South Med J 103(10), 1052 (with rosuvastatin)

Tendinopathy/Tendon rupture <2%

(package insert)

Abnormal vision

(2016): Ventimiglia E+, Expert Opin Drug Saf 15(2), 141 [REVIEW]

(2015): Balhara YP+, Indian J Endocrinol Metab 19(4), 451 [REVIEW]

(2013): Wijitsettakul U+, J Med Assoc Thai 96(6), 6835%

Cataract <2%

(package insert)

Conjunctivitis <2%

(package insert)

Cyanopsia

(2011): Lee M, Clin Ther 33(11), 1590 [REVIEW]

Dyschromatopsia 3–11%

(blue-green vision)

(2012): Prescrire Int 21(127), 126

(2003): Prescrire Int 12(65), 98

(2002): Coelho OR, Int J Impot Res 14, S54

(2002): Laties A+, Prog Retin Eye Res 21(5), 485 [REVIEW]

(1998): Craig D+, Cleveland Clinic Foundation 52, 96311%

Glaucoma

(2011): Azzouni F+, J Sex Med 8(10), 2894 [REVIEW]

Hallucinations, visual

(2006): Sharma RK+, Am J Kidney Dis 48(1), 128 (1 case)

Macular infarction

(2005): Quiram P+, Graefes Arch Clin Exp Ophthalmol 243(4), 339

Mydriasis <2%

(package insert)

Ocular adverse effect

(2014): Miguel A+, Pharmacoepidemiol Drug Saf 23(3), 221 [REVIEW]

Ocular hemorrhage <2%

(2012): Wirostko BM+, BMJ 344

Ocular pain <2%

(2015): Bai WJ+, Asian J Androl 17(1), 61<1%

Ocular pigmentation <2%

(package insert)

Optic atrophy

(2011): Azzouni F+, J Sex Med 8(10), 2894 [REVIEW]

Optic neuropathy

(2016): Zheng L+, J Neuroophthalmol 36(3), 348

(2013): Galvez-Ruiz A+, Saudi J Ophthalmol 27(4), 241 (10 cases)

(2013): Krashin-Bichler I+, Harefuah (Hebrew) 152(2), 84

(2011): Azzouni F+, J Sex Med 8(10), 2894 [REVIEW]

(2011): Moschos MM+, Case Report Ophthalmol 2(2), 262

(2006): Bella AJ+, Can J Urol 13(5), 3233 [REVIEW]

(2006): Gorkin L+, Int J Clin Pract 60(4), 500<1%

(2006): Wooltorton E, CMAJ 175(4), 355

(2005): Egan RA+, Arch Ophthalmol 123(5), 709

(2005): Gruhn N+, Acta Ophthalmol Scand 83(1), 131

(2005): Pomeranz HD+, J Neuroophthalmol 25(1), 9 (7 cases)

(2003): Prescrire Int 12(65), 98

(2003): Gandhi JS, Ophthalmology 110(9), 1860

(2002): Boshier A+, Int J Clin Pharmacol Ther 40(9), 422

(2002): Dheer S+, J Assoc Physicians India 50, 265

(2002): Pomeranz HD+, Ophthalmology 109(3), 584

(2001): Cunningham AV+, J Neuroophthalmol 21(1), 22

(2000): Egan R+, Arch Ophthalmol 118(2), 291

Photophobia <2%

(2013): Morris CR+, Haematologica 98(9), 1359

Retinal vein occlusion

(2011): Azzouni F+, J Sex Med 8(10), 2894 [REVIEW]

(2009): Pinto LM+, Indian J Chest Dis Allied Sci 51 (4), 249

Retinopathy

(2008): Nencini C+, Eur Rev Med Pharmacol Sci 12(5), 293 [REVIEW]

Scotoma

(2012): Izadi S+, Acta Ophthalmol 90(6), e496 (overdosage)

Uveitis

(2013): Isik M+, Rheumatol Int 33(3), 803

Vision blurred

(2015): Sathyanarayana Rao TS+, Indian J Psychiatry 57(3), 311 (ultra-high-dose abuse)

(2013): Morris CR+, Haematologica 98(9), 1359

(2012): Lederer DJ+, COPD 9(3), 268

(2009): Pinto LM+, Indian J Chest Dis Allied Sci 51 (4), 249

Vision impaired

(2008): Pepin S+, J Neuroophthalmol 28(1), 76

Vision loss

(2005): Med Lett Drugs Ther 47(1211), 49

Visual disturbances

(2017): Dunn L+, Fetal Diagn Ther 41(2), 81 [REVIEW]17%

(2017): Graziano S+, Eur Rev Med Pharmacol Sci 21(1 Suppl), 17 [REVIEW] (passim)

(2013): Morris CR+, Haematologica 98(9), 1359

(2012): Xiao Y+, Cochrane Database Syst Rev 4, CD009427 [REVIEW]

(2006): Fava M+, J Clin Psychiatry 67(2), 2403%

Visual halos

(2002): Potter MJ+, Ophthalmology 109(5), 823

Xerophthalmia <2%

(package insert)

Ear pain <2%

(package insert)

Hearing loss / hypoacusis <2%

(2013): Skeith L+, J Popul Ther Clin Pharmacol 20(2), e128 (with diltiazem and furosemide)

(2011): Khan AS+, Laryngoscope 121(5), 1049

(2010): McGwin G Jr, Arch Otolaryngol Head Neck Surg 136(5), 488

(2007): Mukherjee B+, J Laryngol Otol 121(4), 395

Ototoxicity

(2013): Skeith L+, J Popul Ther Clin Pharmacol 20(2), e128 (with diltiazem and furosemide)

Tinnitus <2%

(2007): Buranakitjaroen P+, J Med Assoc Thai 90(6), 1100

(2002): Hamzavi J+, Wien Klin Wochenschr 114(1-2), 54

Alveolar hemorrhage (pulmonary)

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

Asthma <2%

(package insert)

Bronchitis <2%

(package insert)

Cough <2%

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

Dyspnea 7%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]7% (exacerbation)

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

(2013): Morris CR+, Haematologica 98(9), 1359

(2012): Lederer DJ+, COPD 9(3), 268

Hemoptysis

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

(2013): Nour SM+, Tenn Med 106(3), 34

Hypoxia

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW] (1 case)

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

(2010): Zisman DA+, N Engl J Med 363(7), 6201%

Influenza

(2010): Zisman DA+, N Engl J Med 363(7), 6201%

Laryngitis <2%

(package insert)

Pharyngitis <2%

(package insert)

Pleural effusion

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

Pneumonia

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

(2010): Zisman DA+, N Engl J Med 363(7), 6202%

Pulmonary embolism

(2010): Zisman DA+, N Engl J Med 363(7), 6201%

Respiratory failure

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

(2013): Nour SM+, Tenn Med 106(3), 34

(2010): Zisman DA+, N Engl J Med 363(7), 6201%

Rhinitis 4%

(2016): Ventimiglia E+, Expert Opin Drug Saf 15(2), 141

(2015): Balhara YP+, Indian J Endocrinol Metab 19(4), 451 [REVIEW]

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]4%

(2012): Xiao Y+, Cochrane Database Syst Rev 4, CD009427 [REVIEW]

(2011): Lee M, Clin Ther 33(11), 1590 [REVIEW]

(2003): Berman JR+, J Urol 170(6 Pt 1), 2333

Sinusitis <2%

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW]3%

Stridor

(2015): Dodgen AL+, Drug Healthc Patient Saf 7, 175 [REVIEW] (2 cases)

(2013): Maxey DM+, Pediatr Cardiol 34(7), 1628

Upper respiratory tract infection

(2012): Lederer DJ+, COPD 9(3), 268

(2011): Kennedy SH+, Int Clin Psychopharmacol 26(3), 151

Adverse effects

(2019): Della Camera PA+, Urologia Aug, Epub ahead of print20%

(2018): Shah PC+, Indian J Sex Transm Dis AIDS 39(1), 12%

(2014): Chen H+, Urology 84(1), 51 (mild or moderate)

(2014): Wang RC+, Respir Med 108(3), 531 [REVIEW] (mild to moderate)

(2013): Lasaponara F+, J Sex Med 10(11), 2798 (gastrointestinal)

(2013): Seferian A+, Eur Respir Rev 22(129), 217

(2012): Lowe G+, J Sex Med 9(1), 265

Allergic reactions <2%

(package insert)

Death

(2013): Alekperov RT+, Ter Arkh (Russian) 85(5), 60 (1 case)

(2011): De-Giorgio F+, Am J Forensic Med Pathol 32(4), 310

(2002): Dumestre-Toulet V+, Forensic Sci Int 126(1), 71

Dipsia (thirst) <2%

(package insert)

Infection

(2010): Zisman DA+, N Engl J Med 363(7), 6203%

Side effects

(2012): Fu Q+, J Sex Med 9(1), 28220%

Adverse reactions attributed to entire drug class COVID-19 putative drug

Cutaneous adverse reaction

(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]

Cardiovascular adverse effect

(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]

(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

(2020): Zhang D+, Zhongguo Zhong Yao Za Zhi (Chinese) 45(10), 2275-2286 [REVIEW]

Central Nervous System

Neuropsychiatric disturbances

(2020): García CAC+, Gen Hosp Psychiatry Jun, Online ahead of print [REVIEW]

Gastrointestinal/Hepatic

Gastrointestinal disorder

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Hepatic disorder

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%

Thrombocytopenia

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Adverse effects

(2020): Favilli A+, J Matern Fetal Neonatal Med Jun, Online ahead of print [REVIEW]

(2020): Griffiths G+, Trials 21(1), 544

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Rhodes NJ+, medRxiv Jun, Preprint

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zekarias A+, Drug Saf Sep, Online ahead of print [REVIEW]

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Adverse reactions attributed to entire drug class Phosphodiesterase type 5 (PDE5) inhibitor

Flushing

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

(2016): Gao L+, Int J Gynaecol Obstet 133(2), 139 [REVIEW]

(2016): Jia DD+, Spinal Cord 54(7), 494 [REVIEW]

(2012): Rizio N+, J Spinal Cord Med 35(4), 219 [REVIEW]

Rash

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

Epistaxis (nosebleed)

(2016): Vlastarakos PV+, J Emerg Med 51(5), e103

Nasal congestion

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

Hypotension

(2012): Rizio N+, J Spinal Cord Med 35(4), 219 [REVIEW] (mild)

Central Nervous System

Headache

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

(2016): Gao L+, Int J Gynaecol Obstet 133(2), 139 [REVIEW]

(2016): Jia DD+, Spinal Cord 54(7), 494 [REVIEW]

(2012): Rizio N+, J Spinal Cord Med 35(4), 219 [REVIEW]

Vertigo / dizziness

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

Gastrointestinal/Hepatic

Dyspepsia

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

Nausea

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

Neuromuscular/Skeletal

Back pain

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

Myalgia/Myositis/Myopathy/Myotoxicity

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

Abnormal vision

(2017): Scaglione F+, Clin Ther 39(2), 370 [REVIEW]

Optic neuropathy

(2018): Yafi FA+, Sex Med Rev 6(2), 242 [REVIEW]

Visual disturbances

(2016): Gao L+, Int J Gynaecol Obstet 133(2), 139 [REVIEW]

Adverse effects

(2016): Jiang R+, Zhonghua Nan Ke Xue (Chinese) 22(2), 99 [REVIEW]

Page last updated 07/09/2020

Drug Eruption Mobile Site

Symbol key

Incidence

<1%
1-5%
5-10%
10-15%
15-20%
20-30%
>30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

Breast feeding
Geriatric
Pediatric

^ Back to top